CSL Project Aurora is a significant base fractionation expansion initiative at the Broadmeadows Campus in Victoria, Australia. The project enabled end-to-end manufacturing at the site by supplying the intermediate products from plasma to CSL’s existing immunoglobulin and albumin facilities. The company aligned all products manufactured at Broadmeadows with the global product platform. The facility is the largest of its kind in the CSL network, increasing the site’s capacity to nine times its previous level and reaching the equivalent of over 10 million liters of plasma per year. The facility produces intermediates for immunoglobulin and albumin products, as well as products to treat hemophilia, which are all vital for the global patient community. These products meet the growing global demand for plasma-based therapies, essential for treating conditions such as immunodeficiencies, neurological disorders, and burns. They are used by patients and healthcare professionals worldwide, including cancer patients and patients in need of transplants and surgical procedures. CSL’s investment in this facility underscores its commitment to biopharmaceutical innovation, focusing on developing new therapies and enhancing existing ones.

Based on the full-scale application and integration of the various robotics and automation technologies, CSL is recognized as the 2025 ISPE FOYA Category Winner for Pharma 4.0™ for their Project Aurora in Australia.